Contribute Try STAT+ Today

After months of speculation, Mylan Pharmaceuticals has acknowledged receiving what it called an “information request” from the Federal Trade Commission as part of a “preliminary investigation,” according to a statement from a company spokeswoman. The request was received “months ago,” she added, but declined to specify when that occurred.

The probe is apparently focusing on whether the company attempted to thwart generic competition to its EpiPen allergic-reaction device, which has been the focus of controversy over the past several months after continual price hikes caused growing outrage from consumers and, subsequently, some lawmakers. The probe was first reported by Bloomberg News.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.